Ruiling Su
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ruiling Su has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Boqian Wang1 shared publication
Cheng Zhang
1 shared publicationChengyu Huang
1 shared publication- Chunqiang Dong
Department of Organ Transplantation, The First Affiliated Hospital of Guangxi Medical University
1 shared publication - Dan-Dan Xiong
Department of Pathology, The First Affiliated Hospital of Guangxi Medical University, Nanning, China
1 shared publication Guanmiao Chen
1 shared publication
Latest Publications
- Open Access
- 21 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 49215
Multi-Dimensional Data Integration Reveals the Molecular Mechanism of Metabolic Reprogramming Associated With Low Asparaginase Expression in Hepatocellular Carcinoma
Background: To investigate the impact of low expression of asparaginase (ASPG) in hepatocellular carcinoma (HCC) on tumor metabolic reprogramming, tumor microenvironment interactions, and drug sensitivity, and to assess the potential of ASPG as a tumor suppressor gene through multi-dimensional functional mechanisms. Methods: Thus, ASPG expression in HCC was systemically evaluated by integrating global multi-center mRNA datasets, including RNA-seq and microarray data from 3967 HCCs and 2645 non-HCC samples, single-cell RNA sequencing (scRNA-seq) data from 10 HCCs and 8 adjacent normal tissues, spatial transcriptomics (STs), and internal immunohistochemistry data from 301 HCCs and matched adjacent liver tissues. A CRISPR-mediated gene knockout model was employed to examine the effects of ASPG deletion on HCC cell proliferation. ASPG-associated regulatory pathways were analyzed using Gene Set Enrichment Analysis (GSEA), GeneMANIA, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Changes in ligand–receptor interactions between low-expression ASPG (ASPG-low) and the tumor microenvironment were examined using CellChat, based on scRNA-seq data. Single-cell metabolism (scmetabolism) and single-cell flux estimation analysis (scFEA) were applied to infer metabolic activity and metabolite conversion pathways under ASPG-low conditions. Finally, correlations between ASPG expression and the IC50 values of anticancer drugs were assessed using OncoPredict. Results: Multi-dimensional analyses consistently showed that both ASPG mRNA and protein levels were significantly downregulated in HCC. CRISPR-mediated ASPG knockout was associated with significantly increased cell proliferation. Mechanistically, HCC cells with low ASPG expression were enriched in pathways related to alanine, aspartate, and glutamate metabolism, as well as amino acid biosynthesis, gluconeogenesis, and lipid metabolism. Cell–cell communication analysis revealed strong interactions between ASPG-low malignant hepatocytes and myeloid cells, with significant activation of the MIF–(CD74+CXCR4) and MIF–(CD74+CD44) signaling axes. Metabolic analysis demonstrated that the ASPG-low state was associated with alanine, aspartate, and glutamate metabolism, as well as the citric acid (TCA) cycle, thereby regulating the conversion of the aspartate–asparagine and glutamate–2OG metabolites. ASPG-low HCC was associated with resistance to drugs such as cisplatin, oxaliplatin, and gemcitabine, but increased sensitivity to lapatinib and paclitaxel. Conclusion: Low ASPG expression in HCC may drive aspartate metabolism and reprogramming of the TCA cycle, thereby influencing sensitivity to drug treatment.
- 21 April 2026
- Published by IMR Press in Frontiers in Bioscience-Landmark
- Vol. 31 (4) , 49215
Open AccessMulti-Dimensional Data Integration Reveals the Molecular Mechanism of Metabolic Reprogramming Associated With Low Asparaginase Expression in Hepatocellular Carcinoma
Background: To investigate the impact of low expression of asparaginase (ASPG) in hepatocellular carcinoma (HCC) on tumor metabolic reprogramming, tumor microenvironment interactions, and drug sensitivity, and to assess the potential of ASPG as a tumor suppressor gene through multi-dimensional functional mechanisms. Methods: Thus, ASPG expression in HCC was systemically evaluated by integrating global multi-center mRNA datasets, including RNA-seq and microarray data from 3967 HCCs and 2645 non-HCC samples, single-cell RNA sequencing (scRNA-seq) data from 10 HCCs and 8 adjacent normal tissues, spatial transcriptomics (STs), and internal immunohistochemistry data from 301 HCCs and matched adjacent liver tissues. A CRISPR-mediated gene knockout model was employed to examine the effects of ASPG deletion on HCC cell proliferation. ASPG-associated regulatory pathways were analyzed using Gene Set Enrichment Analysis (GSEA), GeneMANIA, Gene Ontology (GO), and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment. Changes in ligand–receptor interactions between low-expression ASPG (ASPG-low) and the tumor microenvironment were examined using CellChat, based on scRNA-seq data. Single-cell metabolism (scmetabolism) and single-cell flux estimation analysis (scFEA) were applied to infer metabolic activity and metabolite conversion pathways under ASPG-low conditions. Finally, correlations between ASPG expression and the IC50 values of anticancer drugs were assessed using OncoPredict. Results: Multi-dimensional analyses consistently showed that both ASPG mRNA and protein levels were significantly downregulated in HCC. CRISPR-mediated ASPG knockout was associated with significantly increased cell proliferation. Mechanistically, HCC cells with low ASPG expression were enriched in pathways related to alanine, aspartate, and glutamate metabolism, as well as amino acid biosynthesis, gluconeogenesis, and lipid metabolism. Cell–cell communication analysis revealed strong interactions between ASPG-low malignant hepatocytes and myeloid cells, with significant activation of the MIF–(CD74+CXCR4) and MIF–(CD74+CD44) signaling axes. Metabolic analysis demonstrated that the ASPG-low state was associated with alanine, aspartate, and glutamate metabolism, as well as the citric acid (TCA) cycle, thereby regulating the conversion of the aspartate–asparagine and glutamate–2OG metabolites. ASPG-low HCC was associated with resistance to drugs such as cisplatin, oxaliplatin, and gemcitabine, but increased sensitivity to lapatinib and paclitaxel. Conclusion: Low ASPG expression in HCC may drive aspartate metabolism and reprogramming of the TCA cycle, thereby influencing sensitivity to drug treatment.
- Open Access
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
HLA‐F–Based Diagnostic Index for Kidney Transplantation: Clinical Application and Validation
Objective: Acute kidney transplant rejection (AKTR) remains a critical determinant of long‐term allograft survival. Emerging evidence indicates that elevated human leukocyte antigen‐F (HLA‐F) expression is linked to heightened immune injury, highlighting its potential diagnostic and therapeutic relevance. This study aimed to establish an HLA‐F–centered diagnostic model for AKTR to enhance early clinical risk stratification and to identify prognostically informative biomarkers and actionable therapeutic targets. Methods: Transcriptomic datasets from kidney transplant biopsies were retrieved from Gene Expression Omnibus (GEO) and rigorously preprocessed. Differentially expressed genes (DEGs) were identified, and HLA‐F–associated dysregulated genes were used to define transcriptional changes underlying acute rejection. Functional modules linked to HLA‐F were delineated via weighted gene coexpression network analysis (WGCNA), informing the development of a 23‐gene diagnostic signature using a machine learning–based LASSO algorithm. Immune microenvironment profiling was subsequently performed by integrating machine learning–based immune deconvolution methods to quantify immune cell infiltration and assess the associations between the selected genes, immune checkpoint molecules, and tertiary lymphoid structure markers. Results: HLA‐F was markedly upregulated in AKTR and exhibited strong diagnostic potential (AUC = 0.960). Integrative transcriptomic analysis identified 910 HLA‐F–associated dysregulated genes, predominantly enriched in clinically relevant pathways, including arachidonic acid metabolism, steroid hormone biosynthesis, and collecting duct acid secretion. A 23‐gene HLA‐F–centered diagnostic model was established, demonstrating strong discriminatory performance. Upstream regulatory analysis further revealed L‐tryptophan as a potential modulator of these genes through its targets IDO1 and WARS. Machine learning–based immune deconvolution showed markedly increased immune cell infiltration in the HLA‐F high‐expression group, with infiltration scores exhibiting significant positive correlations with immune checkpoint genes and tertiary lymphoid structure markers. Conclusions: This study established an HLA‐F–centered diagnostic model based on 23 genes that enables quantitative HLA‐F scoring and improves risk stratification for AKTR. Beyond its diagnostic utility, the model defines a structured molecular feature set that may serve as a preliminary strategic basis for future artificial intelligence–driven drug screening efforts, pending further experimental and clinical validation.
- 1 January 2026
- Published by Wiley in International Journal Of Clinical Practice
- Vol. 2026 (1)
Open AccessHLA‐F–Based Diagnostic Index for Kidney Transplantation: Clinical Application and Validation
Objective: Acute kidney transplant rejection (AKTR) remains a critical determinant of long‐term allograft survival. Emerging evidence indicates that elevated human leukocyte antigen‐F (HLA‐F) expression is linked to heightened immune injury, highlighting its potential diagnostic and therapeutic relevance. This study aimed to establish an HLA‐F–centered diagnostic model for AKTR to enhance early clinical risk stratification and to identify prognostically informative biomarkers and actionable therapeutic targets. Methods: Transcriptomic datasets from kidney transplant biopsies were retrieved from Gene Expression Omnibus (GEO) and rigorously preprocessed. Differentially expressed genes (DEGs) were identified, and HLA‐F–associated dysregulated genes were used to define transcriptional changes underlying acute rejection. Functional modules linked to HLA‐F were delineated via weighted gene coexpression network analysis (WGCNA), informing the development of a 23‐gene diagnostic signature using a machine learning–based LASSO algorithm. Immune microenvironment profiling was subsequently performed by integrating machine learning–based immune deconvolution methods to quantify immune cell infiltration and assess the associations between the selected genes, immune checkpoint molecules, and tertiary lymphoid structure markers. Results: HLA‐F was markedly upregulated in AKTR and exhibited strong diagnostic potential (AUC = 0.960). Integrative transcriptomic analysis identified 910 HLA‐F–associated dysregulated genes, predominantly enriched in clinically relevant pathways, including arachidonic acid metabolism, steroid hormone biosynthesis, and collecting duct acid secretion. A 23‐gene HLA‐F–centered diagnostic model was established, demonstrating strong discriminatory performance. Upstream regulatory analysis further revealed L‐tryptophan as a potential modulator of these genes through its targets IDO1 and WARS. Machine learning–based immune deconvolution showed markedly increased immune cell infiltration in the HLA‐F high‐expression group, with infiltration scores exhibiting significant positive correlations with immune checkpoint genes and tertiary lymphoid structure markers. Conclusions: This study established an HLA‐F–centered diagnostic model based on 23 genes that enables quantitative HLA‐F scoring and improves risk stratification for AKTR. Beyond its diagnostic utility, the model defines a structured molecular feature set that may serve as a preliminary strategic basis for future artificial intelligence–driven drug screening efforts, pending further experimental and clinical validation.